motionpharmacy.com – FDA Warning Letter, Sep 1, 2025

On September 10, 2025, the U.S. Food and Drug Administration (FDA) issued a Warning Letter to motionpharmacy.com, identifying significant violations related to the online sale of unapproved and misbranded drugs to U.S. consumers. The FDA"s review of the website found that motionpharmacy.com was introducing various concerning drug products into interstate commerce.

The primary violations stem from the sale of unapproved new drugs and misbranded drugs, specifically including opioids (such as hydrocodone, oxycodone, and hydromorphone), benzodiazepines, Schedule II stimulants, and injectable semaglutide products. The FDA emphasized the severe public health risks associated with these drugs, citing the ongoing opioid epidemic, the high potential for abuse and overdose with opioids, benzodiazepines, and stimulants, and the dangers of injectable products bypassing the body"s natural defenses, which could lead to serious infections. Unapproved drugs lack the FDA"s assurances of safety and effectiveness, potentially being contaminated, counterfeit, or containing incorrect ingredients.

These activities violate several sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act), including provisions pertaining to the introduction of unapproved new drugs into interstate commerce. The FDA mandates that motionpharmacy.com immediately cease offering all unapproved and misbranded drugs for sale to U.S. consumers to safeguard public health.